The main studied molecular biomarkers are: HER2 overexpression/HER2 gene amplification, PD-L1 expression, microsatellite instability (MSI) status/mismatch repair (MMR) status, and tumour mutation burden (TMB). This evidence concerns the gene ERBB2 and neoplasm.